A poster on Yahoo states that he confirmed with several hospitals that open enrollment continues for Leronlimab. If CD12 had failed, I cannot imagine that NP and the FDA would allow open enrollment to continue. So to me that would mean either that the data remains unblinded or that the trial was determined to be a success. If the data remained unblinded 5 weeks after day 28 (ie today) that would really shock me. Therefore, I conclude that CD12 was determined to be successful. The margin of success is the outstanding question requiring a PR, like by tomorrow please!